Management of multiple myeloma: a systematic review and critical appraisal of published studies.

[1]  N. Clausen,et al.  Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis. , 2009, Scandinavian journal of haematology.

[2]  S. Woolf,et al.  Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Kyle,et al.  Current therapy for multiple myeloma. , 2002, Mayo Clinic proceedings.

[4]  E. Thiel,et al.  Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Esmail,et al.  The Role of High-Dose Chemotherapy and Stem-Cell Transplantation in Patients with Multiple Myeloma: A Practice Guideline of the Cancer Care Ontario Practice Guidelines Initiative , 2002, Annals of Internal Medicine.

[6]  K. Van Steen,et al.  Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? , 2002, The Lancet. Oncology.

[7]  I. Chalmers,et al.  The Landscape and Lexicon of Blinding in Randomized Trials , 2002, Annals of Internal Medicine.

[8]  Karen A Robinson,et al.  Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. , 2002, International journal of epidemiology.

[9]  H. Gerhartz,et al.  Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914) , 2001, British journal of haematology.

[10]  I. Hozo,et al.  Evaluation and appraisal of randomized controlled trials in myeloma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  B. Djulbegovic.  Acknowledgment of uncertainty: A fundamental means to ensure scientific and ethical validity in clinical research , 2001, Current oncology reports.

[12]  D. Altman,et al.  Systematic reviews in health care : meta-analysis in context , 2001 .

[13]  H. Rugo,et al.  Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[15]  J. Harousseau,et al.  Randomized trial experience of the Intergroupe Francophone du Myélome. , 2001, Seminars in hematology.

[16]  G. Tricot,et al.  Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma. , 2001, Seminars in hematology.

[17]  B. Barlogie,et al.  Thalidomide in the management of multiple myeloma. , 2001, Seminars in oncology.

[18]  J. Kanis,et al.  Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma , 2001, British journal of haematology.

[19]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[20]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[21]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[22]  F. Dammacco,et al.  Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma , 2001, British journal of haematology.

[23]  R E Coleman,et al.  Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases , 2001, Cancer.

[24]  R. Collins,et al.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.

[25]  E. Terpos,et al.  Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma , 2000, European journal of haematology.

[26]  Alan Cantor,et al.  The uncertainty principle and industry-sponsored research , 2000, The Lancet.

[27]  C. Tinelli,et al.  Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study , 2000, British Journal of Cancer.

[28]  G. Gahrton,et al.  Syngeneic transplantation in multiple myeloma – a case-matched comparison with autologous and allogeneic transplantation , 1999, Bone Marrow Transplantation.

[29]  A. Grañena,et al.  Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. , 1999, Blood.

[30]  B. Djulbegovic,et al.  The quality of medical evidence in hematology-oncology. , 1999, The American journal of medicine.

[31]  Bernard,et al.  VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide–prednisone therapy (protocol MY 85) , 1998, British journal of haematology.

[32]  P. Ravaud,et al.  High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. , 1998, Blood.

[33]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[34]  J. Ford,et al.  Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trial , 1998, British journal of haematology.

[35]  B. Barlogie,et al.  Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Dunn,et al.  A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma , 1998, British journal of haematology.

[37]  R. Bell,et al.  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B. Barlogie,et al.  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.

[39]  R. Marcus,et al.  Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. , 1996, Blood.

[40]  I. Olkin,et al.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.

[41]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[42]  J. A. Sánchez,et al.  Mobilization of peripheral blood progenitor cells by cyclophosphamide and rhGM-CSF in multiple myeloma. , 1996, Bone marrow transplantation.

[43]  E. Ascari,et al.  Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma. , 1996, British Journal of Cancer.

[44]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[45]  L. Kalish,et al.  Phase III Study Comparing Vincristine, Doxorubicin (Adriamycin), and Dexamethasone (VAD) Chemotherapy with VAD Plus Recombinant Interferon Alfa‐2 in Refractory or Relapsed Multiple Myeloma: An Eastern Cooperative Oncology Group Study , 1995, American journal of clinical oncology.

[46]  R. Kyle,et al.  Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. , 1995, Archives of internal medicine.

[47]  J. Bland,et al.  Statistics notes: Absence of evidence is not evidence of absence , 1995 .

[48]  F. Dammacco,et al.  Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma , 1995, Annals of Hematology.

[49]  J. Reilly,et al.  A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. , 1995, Leukemia & lymphoma.

[50]  J. Crowley,et al.  A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study , 1995, Cancer.

[51]  M. Di Stasi,et al.  Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma. , 1994, British Journal of Cancer.

[52]  K. Dickersin,et al.  Systematic Reviews: Identifying relevant studies for systematic reviews , 1994 .

[53]  D. Ettinger,et al.  Timed‐sequential high‐dose cyclophosphamide and vincristine in the treatment of multiple myeloma , 1994, Cancer.

[54]  E. Holmberg,et al.  Initial versus deferred melphalan‐prednisone therapy for asymptomatic multiple myeloma stage I — A randomized study , 1993, European journal of haematology.

[55]  M. Laakso,et al.  Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma , 1992, The Lancet.

[56]  I. Maclennan,et al.  Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis , 1992, The Lancet.

[57]  B. Zee,et al.  Effect of daily etidronate on the osteolysis of multiple myeloma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  E. Holmberg,et al.  Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan‐prednisone , 1990, British journal of haematology.

[59]  A. Willan,et al.  A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. , 1988, British Journal of Cancer.

[60]  J. Buring,et al.  Epidemiology in Medicine , 1987 .

[61]  E. Ascari,et al.  Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. , 1986, European journal of cancer & clinical oncology.

[62]  H. Silberman,et al.  Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  I. Maclennan,et al.  Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. , 1985, British Journal of Cancer.

[64]  T. Pajak,et al.  Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experience , 1982, Cancer.

[65]  T. Pajak,et al.  Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. , 1982, Cancer treatment reports.

[66]  T. Pajak,et al.  Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU. , 1979, Cancer treatment reports.

[67]  T. Pajak,et al.  Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. , 1979, Blood.

[68]  R. Kyle,et al.  Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). , 1975, Cancer chemotherapy reports.

[69]  H. Wilson,et al.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.

[70]  S. Rivers,et al.  Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. , 1969, JAMA.

[71]  L. Lasagna,et al.  A controlled trial of urethane treatment in multiple myeloma. , 1966, Blood.

[72]  D. Fitzwilliams.  Cancer of the Breast , 1937 .

[73]  Douglas G. Altman,et al.  Systematic Reviews in Health Care , 2001 .

[74]  H. Johnsen,et al.  Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. , 2000, Blood.

[75]  J Gabbay,et al.  'Early warning systems' for identifying new healthcare technologies. , 1999, Health technology assessment.

[76]  P. Tugwell,et al.  Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. , 1999, Health technology assessment.

[77]  Mike Clarke,et al.  Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  A. Pileri,et al.  The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy , 1998, International journal of clinical & laboratory research.

[79]  R. Kato,et al.  A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma , 1997, Cancer Chemotherapy and Pharmacology.

[80]  L. Edler,et al.  Prospective Randomized Trial of Dichloromethylene Bisphosphonate (Clodronate) in Patients with Multiple Myeloma Requiring Treatment. A Multicenter Study , 1995 .

[81]  A. Newland,et al.  Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. , 1992, European journal of cancer.

[82]  Associação Paulista de Medicina.  Revista paulista de medicina , 1941 .